Is VTRS or VYNE more undervalued in 2026?

CirclFi compares Viatris Inc. (VTRS) and VYNE Therapeutics Inc. (VYNE) using 13 institutional-grade valuation models. VTRS has a Quality of Company score of 3.0/10 while VYNE scores 4.6/10.

Which is a better buy — VTRS or VYNE?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do VTRS and VYNE valuations compare?

VTRS at $16.26 and VYNE at $0.68 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

VTRS vs VYNE Valuation Comparison 2026 — Intrinsic Value Analysis

VTRS

Pharmaceutical Preparations

Viatris Inc.

Quality

3.0

out of 10

Value Trap

SAFE

Price

$16.26

Last close

Models

13/13

Active

VYNE

Pharmaceutical Preparations

VYNE Therapeutics Inc.

Quality

4.6

out of 10

Value Trap

LOW

Price

$0.68

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	VTRS Fair Value	VTRS Upside	VYNE Fair Value	VYNE Upside
Bayesian DCF	Intrinsic	$0.91	-94.4%	$0.58	-14.7%
Earnings Power Value	Intrinsic	$10.77	-32.5%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$11.96	-25.0%	$2.33	+242.3%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for VTRS vs VYNE — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

VTRS vs VYNE — Which Stock Is More Undervalued?

VYNE scores higher with a 4.6/10 quality rating vs VTRS's 3.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Viatris Inc. (VTRS) and VYNE Therapeutics Inc. (VYNE) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

VTRS currently trades at $16.26 with a QOC of 3.0/10, while VYNE trades at $0.68 with a QOC of 4.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).